Ignite Creation Date:
2024-05-06 @ 7:47 PM
Last Modification Date:
2024-10-26 @ 3:13 PM
Study NCT ID:
NCT06131489
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-11-14
First Post:
2023-11-09
Brief Title:
Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement
Sponsor:
Beijing Friendship Hospital
Organization:
Beijing Friendship Hospital
Study Overview
Official Title:
Efficacy and Safety of Segmental Resection Combined With the DEP Regimen for Epstein-Barr Virus Associated Hemophagocytic Lymphohistiocytosis With Intestinal Involvement
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
EBV-HLH is a rare disease with high mortality especially for those with intestinal involvement In order to reduce disease burden and improve survival of these patients we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen
Detailed Description:
Epstein-Barr virus associated hemophagocytic lymphohistiocytosis is a rare disease with high mortality especially for those with intestinal involvement Some of them still died despite early control of the disease due to severe complications such as gastrointestinal bleeding In order to reduce disease burden and improve survival of these patients we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None